logo-loader
viewBod Australia Ltd

Bod Australia crosses a major milestone in developing cannabis wafer

The sublingual cannabis wafer is a unique combination of Bod’s proprietary ECs315 cannabis extract and iX Biopharma’s ‘WaferiX’ technology.

cannabidiol medicines
Aiming to sell or license to major pharmaceutical companies

Bod Australia Ltd (ASX:BDA) has formulated a proprietary, sublingual cannabis wafer in association with its partner, specialty pharmaceutical company iX Biopharma (SGX:42C).

The manufacture of the required cannabis wafers for clinical trials is set to commence in the coming weeks, with phase I clinical trials to commence shortly thereafter.

Bod chief executive officer Jo Patterson said: “Having finalised the formulation of Medicabilis in WaferiX form we have another major milestone for the company as it tracks towards the commencement of its phase I clinical trial program.”

READ: Bod Australia gains access to more than 2,000 pharmacies through API deal, shares up 26%

The sublingual cannabis wafer is a unique combination of Bod’s proprietary ECs315 cannabis extract and iX Biopharma’s ‘WaferiX’ technology.

The formulated product, containing Bod’s proprietary cannabis extract, which has been freeze dried into a sublingual wafer, can be placed under the patient's tongue.

The wafer dissolves rapidly and releases contained active compounds for efficient absorption.

The upcoming phase I clinical trial will test the safety, tolerability and pharmacokinetics of Bod’s proprietary Ecs315 extract presented as a sublingual wafer.

Aiming to sell or license to major pharmaceutical companies

A positive trial outcome will leave the company with a unique, patent protected, standardised and reproducible cannabis product which may be sold or licenced to major pharmaceutical companies.

Meanwhile, the company is expected to receive Swiss herbal extracts company Linnea SA’s proprietary cannabidiol (CBD) in MCT oil in the coming weeks.

Following delivery, Bod will make the oil available to patients through the Therapeutic Goods Administration (TGA) Special Access Scheme Category B.

Bod's proposed packaging for the ECs315 CBD extract in MCT oil

Patterson added: “We look forward to receiving our initial order of cannabis oils into Australia and ensuring that it is prescribed and distributed, not only to those that require it, but also in a fully transparent manner.”

Quick facts: Bod Australia Ltd

Price: 0.22 AUD

ASX:BDA
Market: ASX
Market Cap: $20.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus Ltd 'in good shape' with minimal disruption to supply chain as it...

Admedus Ltd's (ASX:AHZ) Wayne Paterson caught up with Proactive's Andrew Scott to discuss the steps and precautions the firm's taking in the wake of the recent virus outbreak. The company's just announced the hospital discharge of the first patient following its clinical surgical aortic valve...

15 hours, 38 minutes ago

2 min read